Navigation Links
GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
Date:10/15/2007

First FDA Approved Oral Therapy Will Allow Patients to be Treated for This

Aggressive Cancer at Home

PHILADELPHIA, Oct. 15 /PRNewswire-USNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today approval by the U.S. Food and Drug Administration (FDA) for oral HYCAMTIN(R) (topotecan) capsules for the treatment of relapsed small cell lung cancer (SCLC).

Specifically, HYCAMTIN capsules are indicated for patients who had a complete or partial response to first-line chemotherapy and who are at least 45 days from the end of that treatment. HYCAMTIN capsules are the only oral single-agent chemotherapy approved for the treatment of SCLC after failure of first-line therapy. The product will be available in 2008.

"The approval of HYCAMTIN capsules is particularly important for patients with relapsed small cell lung cancer as they now have an effective treatment option that has been shown to provide a survival benefit and can be conveniently taken at home," said Debasish Roychowdhury, M.D., Vice President, Global Clinical Development, Oncology Medicine Development Center, GSK. "Additionally, this milestone underscores GSK Oncology's commitment to helping improve cancer patients' quality of life."

This approval was based on positive results from a Phase III study comparing HYCAMTIN capsules plus best supportive care (BSC) to BSC alone in patients with relapsed SCLC, in addition to Phase II and Phase III supporting studies. Best supportive care refers to treatments intended to control, prevent and relieve disease complications to improve comfort and quality of life for the patient, but are not intended to have any anti-tumor effects. In the pivotal Phase III clinical trial, HYCAMTIN capsules added to BSC were associated with prolonged survival in patients with relapsed SCLC. This was the first randomized study ever to demonstrate that patients with relapsed SCLC live longer when they are treated with BSC and chemotherapy com
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... corporate image and impressive new product developments at the Special ... "After ten years of unerring focus on product literature databases ... need to mark the occasion," said founding director ... some interesting developments of benefit to our clients and what ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
(Date:5/21/2013)... 2013 iHealth Lab Inc., a pioneer ... healthcare products and a powerful integrated mobile app ... of two new fitness products to its existing ... the Wireless Pulse Oximeter and Wireless Activity and ... iHealth Lab is also excited ...
Breaking Medicine Technology:Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3
(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...
(Date:5/21/2013)... Melbourne, Australia (PRWEB) May 22, 2013 ... has made the Fertility Clinics industry one ... The industry assists patients who are unable to conceive ... common and popular of which is in-vitro fertilisation (IVF) ... completed IVF cycles in Australia has increased by 4.4% ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... of sleep apnea in children, and while removing them ... kids, it did help them with sleep, behavior and ... apnea is a condition that causes abnormal pauses in ... in sleep with the surgery, and those improvements were ...
(Date:5/21/2013)... for research and economic development will urge congressional ... of supercomputers designed to tackle complex societal questions, ... Daniel Reed will appear at a hearing on ... Energy, titled, "America,s Next Generation Supercomputer: The Exascale ... Room 2318 of the Rayburn House Office Building ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... be at increased risk of suffering depression after giving ... hope they can use the findings to develop a ... are vulnerable to postpartum depression, which affects around 15 ... the May 21 issue of the journal Molecular ...
Breaking Medicine News(10 mins):Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Iowa VP for Research addresses next-generation supercomputers at congressional hearing 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 3
... YORK, Jan. 7 The American Stock Exchange ... the common,stock (the "Securities") of Samaritan Pharmaceuticals, Inc. ... on Form 25 to strike the Securities,from listing ... The,delisting will become effective on January 17, 2008 ...
... 7 Boston Scientific,Corporation (NYSE: BSX ) today ... affirmed a District Court ruling which found that the,NIR(R) ... Johnson & Johnson.,The Appeals Court also reversed the District ... the infringement of that claim. The Appeals,Court remanded the ...
... Science (CCTS) has announced the recipients of its 2008 ... $25,000 from the center to fund early studies in ... trials. The CCTS and the grant program are in ... and Translational Science Award the university received from the ...
... problems surfaced in people with no history of heart ... with no history of heart problems who felt extremely ... heart problems in the three years following the attacks, ... an immediate lethal heart attack in some people, it ...
... Jan. 7 ReBuilder,Medical Technologies, Inc. (Pink Sheets: ... Award. RBRM,s President, David B.,Phillips, Ph.D., was selected ... Award, produced by William Shatner. The initial public ... 2008. Dr. Phillips was,selected because of his state ...
... Blades, Inc. and its,medical device division IncisionTech announced ... Sons, Inc. The acquisition of Popper, a leading,specialty ... the combined company the leading contract manufacturer of ... Specialty Blades,originally announced its intention to acquire Popper ...
Cached Medicine News:Health News:Boston Scientific Announces Court Decision 2Health News:Rockefeller University's Center for Clinical and Translational Science funds pilot studies 2Health News:High Levels of Stress After 9/11 Raised Heart Disease Risk 2Health News:High Levels of Stress After 9/11 Raised Heart Disease Risk 3Health News:ReBuilder Medical Technologies, Inc. Announces Televised Broadcast 2
Scoville Ruptured Disc Curettes, length 10" (254 mm), cup size 4 x 10 mm....
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Bone Curette, 160 mm...
Medicine Products: